167264-41-7

Upstream product

• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 73899-15-7 1-(t-butyldimethylsilyloxy)-2-(4-bromophenyl)ethane 
• 68-12-2 N,N-dimethyl-formamide 
• 4654-39-1 4-bromophenethanol 

Downstream Products

• 167264-35-9 (E)-methyl 3-(4-(2-(tert-butyldimethylsilyloxy)ethyl)phenyl)acrylate 
• 1353660-59-9 (2S,3S)-methyl 3-amino-3-(4-(2-(tert-butyldimethylsilyloxy)ethyl)phenyl)-2-methoxypropanoate 
• 1353660-50-0 (2S,3S)-methyl 3-azido-3-(4-(2-(tert-butyldimethylsilyloxy)ethyl)phenyl)-2-methoxypropanoate 
• 1353660-41-9 (2S,3S)-methyl 3-azido-3-(4-(2-(tert-butyldimethylsilyloxy)ethyl)phenyl)-2-hydroxypropanoate 
• 1353660-33-9 (2S,3R)-methyl 3-(4-(2-(tert-butyldimethylsilyloxy)ethyl)phenyl)-2,3-dihydroxypropanoate 
• 1353660-78-2 C₅₃H₈₂N₄O₁₀Si 
• 1353660-72-6 C₃₈H₅₆N₄O₈Si 
• 1353660-68-0 C₃₉H₅₈N₄O₈Si 

Relevant academic research and scientific papers

Synthesis of chondramide a analogues with modified β-tyrosine and their biological evaluation

Starting from cinnamates 9, obtained by Wittig reaction or Heck coupling, the diols 17 were prepared by asymmetric dihydroxylation. This was followed by a regioselective substitution of the 3-OH group with hydrazoic acid under Mitsunobu conditions. Methylation of the 2-OH group and reduction of the azide group led to the β-tyrosine derivatives 8. Condensation with the dipeptide acid 6 furnished the tripeptide part of the chondramides. The derived acids 21 were combined with the hydroxy ester 7 to the esters 22. Cleavage of the tert-butyl groups and intramolecular lactam formation gave rise to the chondramide A analogues 2 b-k. Growth inhibition assays showed most of the analogues to be biologically active. Some of them even reach the activity of jasplakinolide. It can be concluded that the 4-position of the aryl ring in the β-tyrosine of chondramide A tolerates structural modifications quite well.

CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF

The present invention provides a novel carboxylic acid compound, a salt thereof or a hydrate of them useful as an insulin sensitizer, and a medicament comprising the compound as an active ingredient. That is, the present invention provides a carboxylic acid compound represented by the following formula, a salt thereof, an ester thereof or a hydrate of them. Wherein R1 represents a hydrogen atom, hydroxyl group, halogen, carboxyl group, or a C1-6 alkyl group etc., each of which may have one or more substituents; L represents a single bond, or a C1-6 alkylene group, a C2-6 alkenylene group or a C2-6 alkynylene group, each of which may have one or more substituents; M represents a single bond, or a C1-6 alkylene group, a C2-6 alkenylene group or a C2-6 alkynylene group, each of which may have one or more substituents; T represents a single bond, or a C1-3 alkylene group, a C2-3 alkenylene group or a C2-3 alkynylene group, each of which may have one or more substituents; W represents a carboxyl group;- - - represents a single bond etc. ; X represents a single bond, oxygen atom, a group represented by -NRX1CQ1O- (wherein Q1 represents an oxygen atom or sulfur atom; and RX1 represents a hydrogen atom, formyl group, or a C1-6 alkyl group etc., each of which may have one or more substituents), -OCQ1NRX1- (wherein Q1 and RX1 are as defined above), -CQ1NRx1O- (wherein Q1 and RX1 are as def ined above), ONRX1CQ1- (wherein Q1 and RX1 are as defined above), - Q2SO2- (wherein Q2 is an oxygen atom or -NRX10- (wherein RX10 represents a hydrogen atom, formyl group, or a C1-6 alkyl group etc., each of which may have one or more substituents)) or -SO2Q2- (wherein Q2 is as defined above), (wherein, provided that RX2 and RX3, and/or RX4 and RX5 may together form a ring, Q3 and Q4 are the same as or different from each other and each represents an oxygen atom, (O)S(O) or NRX10 (wherein NRX10 is as defined above)); Y represents a 5- to 14-membered aromatic group etc., which may have one or more substituents and one or more hetero atoms; and the ring Z represents a 5-to 14-membered aromatic group which may have 0 to 4 substituents and one or more hetero atoms, and wherein part of the ring may be saturated.